JUL 24, 2018 03:40 PM PDT

Therapeutic Target For Kidney Cancers

WRITTEN BY: Nouran Amin

The image shows clear cell renal cell carcinoma with ZHX2 highlighted in brown. Credit: Jing Zhang, PhD

Researchers at Lineberger Comprehensive Cancer Center in University of North Carolina revealed a therapeutic target for kidney cancers that share a common genetic change. The researchers knew prior to their study that this genetic change can form plenty of blood vessels that feed tumors and support their survival. Genetic changes that lead to a loss-of-function in a tumor suppressor gene is present in 90 percent of the most common type of kidney cancers. In the study published in journal Science, researchers were able to identify a downstream effect of this particular genetic change that is aiding in kidney cancer formation. In particular, they discovered a protein called ZHX2, this protein over-accumulates in kidney cancer cells and helps to activate other signals involved in cancer growth. The findings suggest that ZHX2 may serve as a potential new therapeutic target for drug development in tretaing clear cell renal cell carcinoma; the most common type of kidney cancer. "If you lose VHL (a tumor suppressor gene), you will accumulate lots of this ZHX2 protein, which will turn on signals that promote kidney cancer," said UNC Lineberger's Qing Zhang, PhD, an assistant professor in the UNC School of Medicine Department of Pathology & Laboratory Medicine and Pharmacology. "This protein could be a potential therapeutic target used to treat kidney cancer on its own or in combination. The next step is to try to figure out how we can target it therapeutically."

Renal cell clear cell carcinoma is responsible for about 70 percent of all kidney cancer cases and about 90 percent of patients diagnosed with clear cell renal cell carcinoma have mutations that lead to the loss-of-function of VHL. When VHL loses its function, blood vessels are triggered to grow. "VHL is the most important tumor suppressor in clear cell renal cell carcinoma," Zhang said. "There are extensive reports showing that from initiation to tumor progression to metastasis -- during the whole process of kidney cancer development -- VHL plays a central role. It is important to understand how the VHL loss contributes to kidney cancer, and how we can therapeutically target the downstream effects of this loss in kidney cancer. We wanted to understand, once VHL is lost, what else in kidney cancer cells is promoting oncogenesis?" Zhang said. "Therapeutically speaking, we're trying to understand how we can target these novel signaling pathways, once we identify them."

UNC Lineberger's William Kim, MD, explains that there has been major advances in treating kidney cancer that include molecularly-targeted therapies and immune-based treatments. But, new treatments are needed for patients with the metastatic form of the disease. "The vast majority of kidney cancers have mutations in VHL, so it makes it a very important gene to investigate," said Kim, who is an associate professor of medicine and genetics in the UNC School of Medicine. "In the last decade or more, we've had quite a number of major treatment advances in kidney cancer. There are nearly a dozen FDA-approved treatments now for this disease, but many of them are similar. Studies like this are important because they delineate the underlying biology of kidney cancer and identify novel, distinct pathways to develop drugs against."

 

Source: UNC Lineberger Comprehensive Cancer Center

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Anticholinergic Drugs and Dementia?
A link between anticholinergic drug use and cognitive impairment was recently observed from observational studies on randomized clinical trials. Regenstrie...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Does Microdosing Really Boost Productivity and Creativity?
Microdosing is the practice of ingesting very low doses of psychedelic substances, typically a twentieth of a recreational dose. In particular, Lysergic ac...
OCT 13, 2019
Health & Medicine
OCT 13, 2019
FDA Approves New Treatment for Extensively Drug-Resistant TB
Last week, the U.S. Food and Drug Administration (FDA) approved a new treatment for a severe form of multi-drug-resistant tuberculosis of the lungs. Accord...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Does Adderall Really Work for People without ADHD?
Adderall is a popular stimulant. Known to treat Attention Deficit Disorder (ADHD), those without the condition also use it to increase attention, focus and...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Does TruBrain Really Work?
TruBrain is a mix of different substances claimed to help people increase verbal fluency, avoid distractions, and boost their mental output. Created by a t...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Injectable Hydrogel Found Safe for Heart Repair
The first successful in-human clinical trial of an injectable hydrogel that aims to repair heart damage and restore cardiac function was recently conducted...
Loading Comments...